Name | Number of supported studies | Average coverage | |
---|---|---|---|
microglial cell | 5 studies | 22% ± 5% | |
macrophage | 4 studies | 23% ± 3% |
Insufficient scRNA-seq data for expression of LOXL3 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 99% | 457.44 | 179 / 180 | 93% | 7.51 | 402 / 430 |
breast | 98% | 475.23 | 449 / 459 | 93% | 5.77 | 1037 / 1118 |
brain | 91% | 317.17 | 2392 / 2642 | 99% | 15.22 | 697 / 705 |
adrenal gland | 99% | 789.18 | 255 / 258 | 87% | 22.81 | 200 / 230 |
lung | 100% | 690.31 | 576 / 578 | 86% | 4.58 | 988 / 1155 |
intestine | 100% | 758.34 | 962 / 966 | 79% | 3.83 | 415 / 527 |
uterus | 99% | 951.74 | 169 / 170 | 72% | 5.05 | 329 / 459 |
bladder | 100% | 680.67 | 21 / 21 | 70% | 3.44 | 352 / 504 |
stomach | 89% | 337.94 | 320 / 359 | 79% | 3.50 | 227 / 286 |
skin | 70% | 743.70 | 1271 / 1809 | 93% | 63.79 | 438 / 472 |
esophagus | 90% | 577.85 | 1295 / 1445 | 70% | 2.89 | 128 / 183 |
kidney | 90% | 301.30 | 80 / 89 | 65% | 3.65 | 589 / 901 |
prostate | 99% | 533.44 | 243 / 245 | 40% | 1.23 | 201 / 502 |
thymus | 98% | 389.73 | 639 / 653 | 39% | 1.22 | 238 / 605 |
pancreas | 39% | 90.80 | 128 / 328 | 90% | 5.82 | 160 / 178 |
spleen | 100% | 1395.10 | 241 / 241 | 0% | 0 | 0 / 0 |
adipose | 100% | 896.40 | 1203 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 1070.38 | 1331 / 1335 | 0% | 0 | 0 / 0 |
heart | 96% | 608.77 | 830 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 95% | 696.24 | 881 / 929 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 80% | 3.09 | 36 / 45 |
lymph node | 0% | 0 | 0 / 0 | 79% | 4.40 | 23 / 29 |
liver | 23% | 53.50 | 53 / 226 | 12% | 0.41 | 48 / 406 |
muscle | 21% | 44.26 | 171 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 16% | 0.64 | 13 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0001837 | Biological process | epithelial to mesenchymal transition |
GO_0030324 | Biological process | lung development |
GO_0006954 | Biological process | inflammatory response |
GO_0018057 | Biological process | peptidyl-lysine oxidation |
GO_0021510 | Biological process | spinal cord development |
GO_0061053 | Biological process | somite development |
GO_2001046 | Biological process | positive regulation of integrin-mediated signaling pathway |
GO_1905590 | Biological process | fibronectin fibril organization |
GO_0060021 | Biological process | roof of mouth development |
GO_2000329 | Biological process | negative regulation of T-helper 17 cell lineage commitment |
GO_0030199 | Biological process | collagen fibril organization |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0005615 | Cellular component | extracellular space |
GO_0005576 | Cellular component | extracellular region |
GO_0016020 | Cellular component | membrane |
GO_0062023 | Cellular component | collagen-containing extracellular matrix |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0004720 | Molecular function | protein-lysine 6-oxidase activity |
GO_0001968 | Molecular function | fibronectin binding |
GO_0005507 | Molecular function | copper ion binding |
GO_0005515 | Molecular function | protein binding |
Gene name | LOXL3 |
Protein name | Lysyl oxidase like 3 Uncharacterized protein LOXL3 Lysyl oxidase homolog (EC 1.4.3.13) Lysyl oxidase homolog 3 (EC 1.4.3.-) (EC 1.4.3.13) (Lysyl oxidase-like protein 3) Alternative protein LOXL3 |
Synonyms | LOXL |
Description | FUNCTION: Protein-lysine 6-oxidase that mediates the oxidation of peptidyl lysine residues to allysine in target proteins . Catalyzes the post-translational oxidative deamination of peptidyl lysine residues in precursors of elastin and different types of collagens, a prerequisite in the formation of cross-links between collagens and elastin . Required for somite boundary formation by catalyzing oxidation of fibronectin (FN1), enhancing integrin signaling in myofibers and their adhesion to the myotendinous junction (MTJ) (By similarity). Acts as a regulator of inflammatory response by inhibiting differentiation of naive CD4(+) T-cells into T-helper Th17 or regulatory T-cells (Treg): acts by interacting with STAT3 in the nucleus and catalyzing both deacetylation and oxidation of lysine residues on STAT3, leading to disrupt STAT3 dimerization and inhibit STAT3 transcription activity . Oxidation of lysine residues to allysine on STAT3 preferentially takes place on lysine residues that are acetylated . Also able to catalyze deacetylation of lysine residues on STAT3 . .; FUNCTION: [Isoform 1]: Shows protein-lysine 6-oxidase activity toward elastin and different types of collagens, with the highest activity toward collagen type VIII . .; FUNCTION: [Isoform 2]: Shows protein-lysine 6-oxidase activity toward elastin and different types of collagens, with the highest activity toward collagen type IV . . FUNCTION: Mediates the post-translational oxidative deamination of lysine residues on target proteins leading to the formation of deaminated lysine (allysine). . FUNCTION: Mediates the post-translational oxidative deamination of lysine residues on target proteins leading to the formation of deaminated lysine (allysine). . FUNCTION: Mediates the post-translational oxidative deamination of lysine residues on target proteins leading to the formation of deaminated lysine (allysine). . |
Accessions | C9J5M1 ENST00000409549.5 P58215 ENST00000409986.5 L8E911 ENST00000264094.8 [P58215-1] H7C248 ENST00000409249.5 Q53TY1 B8ZZT6 E7END4 ENST00000413469.1 ENST00000393937.6 [P58215-3] B9A025 ENST00000420535.1 |